FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076962732> ?p ?o ?g. }

• W2076962732 endingPage "194" @default.
• W2076962732 startingPage "180" @default.
• W2076962732 abstract "To evaluate the durability of improvement and long-term efficacy of milnacipran treatment in fibromyalgia, to assess efficacy in patients re-randomized from placebo to milnacipran, and to collect additional information on the tolerability and efficacy of long-term treatment with milnacipran.A total of 449 patients who successfully completed a 6-month lead-in study enrolled in this 6-month extension study (87.7% of eligible subjects). Patients initially receiving milnacipran 200 mg/day during the lead-in study were maintained at 200 mg/day (n = 209); patients initially assigned to placebo or milnacipran 100 mg/day were re-randomized (1:4) to either 100 mg/day (n = 48) or 200 mg/day (n = 192) of milnacipran for an additional 6 months of treatment. Efficacy assessments included visual analog scale pain ratings, Fibromyalgia Impact Questionnaire (FIQ) total score, and Patient Global Impression of Change (PGIC).Patients continuing on milnacipran demonstrated a sustained reduction in pain over the full 12-month period. Additional beneficial effects were also maintained, as indicated by the PGIC and FIQ. Patients initially assigned to either placebo or milnacipran 100 mg/day in the lead-in study and subsequently re-randomized to milnacipran 200 mg/day in the extension study experienced further improvements in their mean pain scores, FIQ total scores, and PGIC ratings at 1 year. Milnacipran treatment was generally well tolerated. The most commonly reported newly emergent adverse event was nausea.In addition to confirming that milnacipran safely and effectively improves the multiple symptoms of fibromyalgia, these data indicate that milnacipran provides 1-year durable efficacy in this patient population." @default.
• W2076962732 created "2016-06-24" @default.
• W2076962732 creator A5002751796 @default.
• W2076962732 creator A5003434684 @default.
• W2076962732 creator A5017541508 @default.
• W2076962732 creator A5060489101 @default.
• W2076962732 creator A5081778211 @default.
• W2076962732 creator A5084560460 @default.
• W2076962732 date "2010-02-01" @default.
• W2076962732 modified "2023-10-05" @default.
• W2076962732 title "Durability of Therapeutic Response to Milnacipran Treatment for Fibromyalgia. Results of a Randomized, Double-Blind, Monotherapy 6-Month Extension Study" @default.
• W2076962732 cites W1530422538 @default.
• W2076962732 cites W1969313589 @default.
• W2076962732 cites W1972599056 @default.
• W2076962732 cites W1973637626 @default.
• W2076962732 cites W1983433026 @default.
• W2076962732 cites W1990079987 @default.
• W2076962732 cites W1992436256 @default.
• W2076962732 cites W1994241243 @default.
• W2076962732 cites W1995611237 @default.
• W2076962732 cites W2003239266 @default.
• W2076962732 cites W2009137120 @default.
• W2076962732 cites W2018996648 @default.
• W2076962732 cites W2040437210 @default.
• W2076962732 cites W2041481324 @default.
• W2076962732 cites W2059757133 @default.
• W2076962732 cites W2062700118 @default.
• W2076962732 cites W2067495470 @default.
• W2076962732 cites W2069238845 @default.
• W2076962732 cites W2069831723 @default.
• W2076962732 cites W2072856001 @default.
• W2076962732 cites W2093196756 @default.
• W2076962732 cites W2102560768 @default.
• W2076962732 cites W2113214053 @default.
• W2076962732 cites W2113447800 @default.
• W2076962732 cites W2123038093 @default.
• W2076962732 cites W2124677225 @default.
• W2076962732 cites W2128447164 @default.
• W2076962732 cites W2132309748 @default.
• W2076962732 cites W2132370975 @default.
• W2076962732 cites W2135164725 @default.
• W2076962732 cites W2143964550 @default.
• W2076962732 cites W2148029309 @default.
• W2076962732 cites W2253364553 @default.
• W2076962732 cites W228126680 @default.
• W2076962732 cites W2313825065 @default.
• W2076962732 cites W4253631050 @default.
• W2076962732 doi "https://doi.org/10.1111/j.1526-4637.2009.00755.x" @default.
• W2076962732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20002596" @default.
• W2076962732 hasPublicationYear "2010" @default.
• W2076962732 type Work @default.
• W2076962732 sameAs 2076962732 @default.
• W2076962732 citedByCount "57" @default.
• W2076962732 countsByYear W20769627322012 @default.
• W2076962732 countsByYear W20769627322013 @default.
• W2076962732 countsByYear W20769627322014 @default.
• W2076962732 countsByYear W20769627322015 @default.
• W2076962732 countsByYear W20769627322016 @default.
• W2076962732 countsByYear W20769627322017 @default.
• W2076962732 countsByYear W20769627322018 @default.
• W2076962732 countsByYear W20769627322019 @default.
• W2076962732 countsByYear W20769627322020 @default.
• W2076962732 countsByYear W20769627322021 @default.
• W2076962732 countsByYear W20769627322022 @default.
• W2076962732 countsByYear W20769627322023 @default.
• W2076962732 crossrefType "journal-article" @default.
• W2076962732 hasAuthorship W2076962732A5002751796 @default.
• W2076962732 hasAuthorship W2076962732A5003434684 @default.
• W2076962732 hasAuthorship W2076962732A5017541508 @default.
• W2076962732 hasAuthorship W2076962732A5060489101 @default.
• W2076962732 hasAuthorship W2076962732A5081778211 @default.
• W2076962732 hasAuthorship W2076962732A5084560460 @default.
• W2076962732 hasBestOaLocation W20769627322 @default.
• W2076962732 hasConcept C126322002 @default.
• W2076962732 hasConcept C14184104 @default.
• W2076962732 hasConcept C142724271 @default.
• W2076962732 hasConcept C168563851 @default.
• W2076962732 hasConcept C1862650 @default.
• W2076962732 hasConcept C197934379 @default.
• W2076962732 hasConcept C204787440 @default.
• W2076962732 hasConcept C27081682 @default.
• W2076962732 hasConcept C2776000289 @default.
• W2076962732 hasConcept C2777831278 @default.
• W2076962732 hasConcept C2778375690 @default.
• W2076962732 hasConcept C2779177272 @default.
• W2076962732 hasConcept C2780199185 @default.
• W2076962732 hasConcept C2781161787 @default.
• W2076962732 hasConcept C42219234 @default.
• W2076962732 hasConcept C71924100 @default.
• W2076962732 hasConceptScore W2076962732C126322002 @default.
• W2076962732 hasConceptScore W2076962732C14184104 @default.
• W2076962732 hasConceptScore W2076962732C142724271 @default.
• W2076962732 hasConceptScore W2076962732C168563851 @default.
• W2076962732 hasConceptScore W2076962732C1862650 @default.
• W2076962732 hasConceptScore W2076962732C197934379 @default.
• W2076962732 hasConceptScore W2076962732C204787440 @default.
• W2076962732 hasConceptScore W2076962732C27081682 @default.
• W2076962732 hasConceptScore W2076962732C2776000289 @default.

• next